Jazz Pharmaceuticals announces SLEEP publication of phase III Xywav oral solution study in cataplexy or excessive daytime sleepiness in patients with narcolepsy.
Jazz Pharmaceuticals plc announced the publication of the global Phase III double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.